uniQure (NASDAQ:QURE) Director Sells $856,890.84 in Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 31,434 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $27.26, for a total transaction of $856,890.84. Following the completion of the transaction, the director directly owned 40,145 shares of the company’s stock, valued at $1,094,352.70. This represents a 43.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

uniQure Stock Down 5.9%

Shares of QURE traded down $1.64 during mid-day trading on Monday, reaching $26.15. The company’s stock had a trading volume of 3,141,937 shares, compared to its average volume of 2,213,656. uniQure N.V. has a 1 year low of $5.50 and a 1 year high of $71.50. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -6.67 and a beta of 0.59. The business has a fifty day moving average of $42.07 and a 200 day moving average of $24.30.

uniQure (NASDAQ:QURE) last released its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. As a group, analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of QURE. Private Trust Co. NA acquired a new stake in shares of uniQure in the third quarter valued at about $28,000. Jones Financial Companies Lllp lifted its position in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,538 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in uniQure in the 2nd quarter valued at approximately $117,000. Finally, Teacher Retirement System of Texas bought a new position in uniQure in the 2nd quarter worth approximately $151,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. HC Wainwright lowered their price target on shares of uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Guggenheim boosted their target price on uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, September 25th. Stifel Nicolaus raised their price target on uniQure from $30.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Mizuho boosted their price target on uniQure from $30.00 to $60.00 and gave the company an “outperform” rating in a research note on Thursday, September 25th. Finally, Cantor Fitzgerald increased their price objective on uniQure from $47.00 to $80.00 and gave the stock an “overweight” rating in a report on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $66.08.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.